Drug Repurposing of Cyclin-Dependent Kinase Inhibitors for Neutrophilic Acute Respiratory Distress Syndrome and Psoriasis

Cyclin-dependent kinase (CDK) inhibitors, initially developed for cancer treatment, show potential in treating neutrophilic acute respiratory distress syndrome (ARDS) and psoriasis by targeting off-label pathways such as phosphoinositide 3-kinase (PI3K) and phosphodiesterase 4 (PDE4). Drugs like palbociclib and ribociclib have demonstrated efficacy in controlling neutrophilic inflammation. However, their repurposing requires careful consideration of off-target effects and dose optimization. Further exploration and clinical trials are necessary to ensure their safety and efficacy in treating these inflammatory conditions.